

Annarosa Floreani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8440555/publications.pdf>

Version: 2024-02-01

74
papers

4,679
citations

136950

32
h-index

98798

67
g-index

74
all docs

74
docs citations

74
times ranked

4491
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex disparity and drug-induced liver injury. <i>Digestive and Liver Disease</i> , 2023, 55, 21-28.	0.9	5
2	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	3.9	26
3	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	3.9	7
4	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
5	Primary biliary cholangitis: perception and expectation of illness. <i>Digestive and Liver Disease</i> , 2022, 54, 1230-1233.	0.9	1
6	COVID-19 and Autoimmune Liver Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 2681.	2.4	13
7	Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2022, 12, 925.	2.5	10
8	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	4.4	30
9	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.4	14
10	Epstein-Barr Virus (EBV) acute acalculous cholecystitis in an immunocompromised adult patient: a case report and a literature review of a neglected clinical presentation. <i>Journal of Preventive Medicine and Hygiene</i> , 2021, 62, E237-E242.	0.9	0
11	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
12	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	4.4	17
13	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
14	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. <i>Hepatology Communications</i> , 2020, 4, 1257-1262.	4.3	55
15	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3095.	2.6	17
16	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.4	74
17	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
18	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1408-1414.	3.9	22

#	ARTICLE	IF	CITATIONS
19	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	12.1	28
20	<p>Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 643-652.	3.2	6
21	Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. <i>Nutrients</i> , 2019, 11, 1602.	4.1	29
22	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 992-999.	3.7	25
23	In vitro metabolic zonation through oxygen gradient on a chip. <i>Scientific Reports</i> , 2019, 9, 13557.	3.3	52
24	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , 2019, 70, e1-e2.	3.7	18
25	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
26	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	3.7	148
27	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1878-1885.	0.4	24
28	Coronary flow reserve in patients with primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2019, 51, 542-548.	0.9	0
29	Extrahepatic autoimmunity in autoimmune liver disease. <i>European Journal of Internal Medicine</i> , 2019, 59, 1-7.	2.2	27
30	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	1.3	82
31	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. <i>Digestive and Liver Disease</i> , 2018, 50, 698-702.	0.9	21
32	Extrahepatic Malignancies in Primary Biliary Cholangitis. <i>Current Hepatology Reports</i> , 2018, 17, 130-134.	0.9	0
33	Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis. <i>American Journal of Pathology</i> , 2018, 188, 627-639.	3.8	59
34	NI&O801, an anti&Echemokine (C&E&C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 492-503.	4.3	35
35	Primary biliary cholangitis: Old and novel therapy. <i>European Journal of Internal Medicine</i> , 2018, 47, 1-5.	2.2	54
36	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.4	64

#	ARTICLE	IF	CITATIONS
37	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
38	Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study. <i>Frontiers in Physiology</i> , 2018, 9, 1530.	2.8	18
39	Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats via CAR activation. <i>PLoS ONE</i> , 2018, 13, e0204336.	2.5	43
40	Etiopathogenesis of autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2018, 95, 133-143.	6.5	105
41	PBC and related extrahepatic diseases. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 49-54.	2.4	31
42	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
43	How best to manage chronic cholestasis. <i>Journal of Family Practice</i> , 2018, 67, E9-E15.	0.2	0
44	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
45	Geoeidemiology and changing mortality in primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2017, 52, 655-662.	5.1	16
46	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017, 49, 841-846.	0.9	23
47	Heparanase and macrophage interplay in the onset of liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 14956.	3.3	46
48	Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. <i>American Journal of Gastroenterology</i> , 2017, 112, 114-119.	0.4	34
49	Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7519-7530.	3.3	22
50	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). <i>Autoimmunity Reviews</i> , 2016, 15, 795-800.	5.8	31
51	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	27.0	817
52	Environmental Basis of Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 50, 287-300.	6.5	92
53	Proposed therapies in primary biliary cholangitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 371-382.	3.0	10
54	New Insights on Intrahepatic Cholestasis of Pregnancy. <i>Clinics in Liver Disease</i> , 2016, 20, 177-189.	2.1	99

#	ARTICLE	IF	CITATIONS
55	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016, 168, 122-133.	5.0	19
56	Functional differentiation of human pluripotent stem cells on a chip. <i>Nature Methods</i> , 2015, 12, 637-640.	19.0	122
57	Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 801-804.	1.8	6
58	Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 254-262.	6.5	19
59	Pregnancy and Primary Biliary Cirrhosis: A Case-Control Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 236-242.	6.5	34
60	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015, 47, 432-435.	0.9	26
61	Metabolic Syndrome Associated With Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 57-60.	2.2	37
62	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	1.3	330
63	New Therapies for Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 263-272.	6.5	34
64	Extrahepatic Autoimmune Conditions Associated with Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 192-197.	6.5	144
65	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	1.3	365
66	Primary Biliary Cirrhosis: Overlaps with Other Autoimmune Disorders. <i>Seminars in Liver Disease</i> , 2014, 34, 352-360.	3.6	44
67	Sleep-Wake profiles in patients with primary biliary cirrhosis. <i>Liver International</i> , 2013, 33, 203-209.	3.9	36
68	Intrahepatic cholestasis of pregnancy: new insights into its pathogenesis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1410-1415.	1.5	25
69	Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. <i>Hepatology</i> , 2013, 58, 1520-1521.	7.3	10
70	Hepatitis C and pregnancy. <i>World Journal of Gastroenterology</i> , 2013, 19, 6714.	3.3	65
71	Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. <i>European Journal of Epidemiology</i> , 2000, 16, 87-91.	5.7	32
72	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. <i>Cancer</i> , 1999, 85, 2132-2137.	4.1	216

#	ARTICLE	IF	CITATIONS
73	Bone metabolism in orthotopic liver transplantation: A prospective study. Liver Transplantation, 1998, 4, 311-319.	1.8	49
74	Hepatitis in Nursing Homes. Drugs and Aging, 1994, 5, 96-101.	2.7	4